gem nuclear organelle associated protein 2Genealiases: SIP1 · SIP1-delta
Q-omics provides the consensus-scored GEMIN2 profile across patient tissues and cancer cell-line models. GEMIN2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GEMIN2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GEMIN2 RNA expression shows 19,511 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where GEMIN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GEMIN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GEMIN2 survival associations across molecular data types. GEMIN2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GEMIN2 RNA expression–survival associations across cancer types. High GEMIN2 expression shows unfavorable associations in ACC, MESO, LIHC, BLCA, HNSC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GEMIN2 RNA expression.
This table summarizes GEMIN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GEMIN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GEMIN2 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, LUSC and KIRP. The HNSC box plot shows higher GEMIN2 RNA expression in tumor versus normal tissue (log2 FC = +1.060, t-test p < 0.001).
This table shows molecular features associated with GEMIN2 in patient tissues and cancer cell lines. In patient samples, GEMIN2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GEMIN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
